CORALLO, DAMIANO SALVATORE
 Distribuzione geografica
Continente #
NA - Nord America 170
AS - Asia 116
EU - Europa 111
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 401
Nazione #
US - Stati Uniti d'America 164
CN - Cina 64
IT - Italia 55
IE - Irlanda 15
IN - India 14
JP - Giappone 11
FR - Francia 8
GB - Regno Unito 7
SE - Svezia 7
VN - Vietnam 7
IR - Iran 5
SG - Singapore 5
DE - Germania 4
FI - Finlandia 4
NL - Olanda 4
PL - Polonia 4
AU - Australia 3
CA - Canada 3
GT - Guatemala 3
HK - Hong Kong 3
KR - Corea 3
TW - Taiwan 2
AM - Armenia 1
BE - Belgio 1
EU - Europa 1
RU - Federazione Russa 1
TR - Turchia 1
UA - Ucraina 1
Totale 401
Città #
Fairfield 22
Chandler 15
Dublin 15
Woodbridge 13
Houston 11
Beijing 10
Torino 10
Cambridge 9
Guangzhou 8
Seattle 8
Ashburn 7
Dong Ket 7
Mumbai 7
Wilmington 7
San Jose 6
Shanghai 6
Nyköping 5
Oxford 5
Helsinki 4
Nanjing 4
Pisa 4
Warsaw 4
Guatemala City 3
Hangzhou 3
Hong Kong 3
Milan 3
New York 3
Ottawa 3
Rajkot 3
Rome 3
San Diego 3
Tokyo 3
Aioicho 2
Ann Arbor 2
Chagrin Falls 2
Changchun 2
Clermont 2
Kish 2
Lake Forest 2
Lanzhou 2
Leeuwarden 2
Littleton 2
Pontedera 2
Princeton 2
Pune 2
Rivoli 2
Rotterdam 2
Shenyang 2
Singapore 2
Taipei 2
Tampa 2
Villeurbanne 2
Zhengzhou 2
Aradeo 1
Berlin 1
Bernalda 1
Boston 1
Bovisio Masciago 1
Brisbane 1
Brookline 1
Cairate 1
Coimbatore 1
Dearborn 1
Fukushima 1
Genova 1
Gillingham 1
Hebei 1
Himeji 1
Hounslow 1
Jinan 1
Kake 1
Kashan 1
Katy 1
Köln 1
Leawood 1
Malgrate 1
Medford 1
Merelbeke 1
Minato-ku 1
Newcastle 1
Niigata 1
Ningbo 1
Paris 1
Rochester 1
San Mateo 1
Sandwich 1
Shenzhen 1
Somma Lombardo 1
Tianjin 1
Turin 1
Upper Marlboro 1
Venezia 1
Verona 1
Wuhan 1
Yekaterinburg 1
Yerevan 1
Yuncheng 1
Zanè 1
Çorum 1
Totale 305
Nome #
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 224
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 168
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 19
Totale 411
Categoria #
all - tutte 945
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 945


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202079 5 3 2 10 1 6 9 12 13 7 3 8
2020/202169 5 9 7 6 0 8 6 4 2 7 3 12
2021/202274 8 3 7 10 5 2 2 4 5 3 16 9
2022/202392 5 8 5 4 12 11 5 8 16 3 12 3
2023/202460 10 7 1 4 2 12 2 7 5 2 4 4
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 411